EPO peptide mimetics (AplaGen)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameEPO peptide mimetics (AplaGen)
Drug Alias Nameerythropoietin peptide mimetics (AplaGen)SESTideHemoMerAG-EM-0040AGE-53C +[6] 
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionErythropoietin receptor agonistsErythropoietin receptor modulators
TargetsErythropoietin receptor
Therapy Area/IndicationsAnemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAplaGen GmbH
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAplaGen GmbH
Active IndicationsN/A
Inactive IndicationsAnemia

Other Information

ATC CodeN/A
Related LinksN/A